After jumping 22% yesterday on no news, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced today, along with the University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany, a Phase II clinical trial program combining DCVax®-L and Pembrolizumab (Keytruda®) for colorectal cancer with liver metastases.
Northwest shares reacted to today’s news, jumping 9% as of this writing. We advise investors to be cautious as yesterday’s move is a bit suspicious.
Linda Powers, CEO of NW Bio, noted that, “More than 2 years of planning and work have gone into developing this Phase II trial program. We are excited to work with a leading team to test the potential synergies of combining broad spectrum DCVax-L and targeted Pembrolizumab to treat a heterogeneous and challenging disease such as metastatic colorectal cancer.”
The trial will be conducted as an investigator-initiated trial led by the University of Mainz, thereby substantially reducing the costs involved. NW Bio will provide the DCVax-L products and MSD Sharp & Dohme GmbH will provide the Pembrolizumab. (MSD Sharp & Dohme is the operating name used by U.S.-based Merck & Co., Inc. outside the U.S. and Canada.) All of the parties contributed to and approved the novel trial design.
This trial will combine a broad spectrum personalized vaccine (DCVax®-L) with a highly targeted checkpoint inhibitor drug (Pembrolizumab). In contrast, most combination trials to date have combined two specifically targeted agents, with no broad spectrum agent included. (Original Source)
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. It engages in the provision of developing cancer vaccines designed to treat a solid tumor cancers.